Safety profile and potential clinical risks of xanomeline and trospium chloride: A real-world pharmacovigilance study using FAERS
{{output}}
Xanomeline and trospium chloride, the first FDA-approved oral cholinergic therapy for adults with schizophrenia in decades, represents a mechanistic shift in antipsychotic treatment, yet its real-world safety profile remains incompletely defined. Using the FDA... ...
